Pamplona

• A clinical study of MK-6194 for the treatment of vitiligo (MK-6194-007) Ended
  2023-503502-37-00 4 2024-01-24 Non segmental vitiligo
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 Relapsed or Refractory High-Risk Myelodysplastic Syndrome
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• (VELA) Study of BLU-222 in Advanced Solid Tumors Ended
  2022-502528-29-00 7 2024-01-09 HR+ Breast Cancer CCNE1 Amplification HER2-negative Breast Cancer Adva
• A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibul … Ended
  2023-505487-11-00 5 2023-12-21 Actinic Keratosis on the Face or Scalp
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or … Ended
  2023-503689-21-00 9 2023-12-05 Multiple myeloma (MM)
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination with a Checkpoint Inhibitor with or without Stand … Ended
  2022-502615-11-00 1 2023-11-29 Locally Advanced or Metastatic Solid Tumors
• A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular C … Ended
  2022-502840-11-00 9 2023-11-28 Hepatocellular Carcinoma (Morpheus-Neo HCC)
• AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEW … Ended
  2023-504545-31-00 1 2023-11-23 colorectal cancer
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• CHemical OptImization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy 2 (CHOICE2TRIAL) Ended
  2023-504262-32-01 5 2023-11-16 Cerebral Embolectomy in patients with acute stroke
• A Study to Evaluate CC-486 in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Cancer Partic … Ended
  2023-503427-26-00 3 2023-11-10 Myeloid malignancies with moderate or severe hepatic impairment or nor
• A study to see how well PLS240 works in treating secondary hyperparathyroidism, and how safe it is, in end stage kidney disease participants … Ended
  2023-504338-24-00 5 2023-11-09 ESKD participants with history of secondary hyperparathyroidism (SHPT)
• A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) Ended
  2022-502227-22-00 4 2023-10-25 Autoimmune disease
• A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended
  2022-502476-23-00 4 2023-10-25 Treatment of immunotherapy-naive patients with previously untreated or
• Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE) Ended
  2022-501523-24-00 4 2023-10-12 Cutaneous Lupus Erythematosus (CLE)
• A study to test the effect of Samuraciclib in Combination with Elacestrant in Participants with Hormone Receptor-positive (HR+) and Human Ep … Ended
  2023-503846-30-00 9 2023-10-10 Breast Cancer
• Study of GS-4528 for Adults With Solid Tumors Ended
  2022-502070-16-00 1 2023-10-02 Solid Tumors
• A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended
  2023-503576-25-00 5 2023-09-22 Severe Hypertriglyceridemia
• A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended
  2022-502174-16-00 5 2023-09-13 Macular edema secondary to retinal vein occlusion
• A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Ended
  2022-501476-25-00 5 2023-09-12 Atopic Dermatitis Eczema
• Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to … Ended
  2022-501918-55-00 4 2023-09-12 Mild Alzheimer's disease
• EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Met … Ended
  2024-515407-19-00 5 2023-08-16 Metastatic pancreatic ductal adenocarcinoma (mPDAC)

Showing 673–696 of 821 trials